Palisade Capital Management’s AstraZeneca AZN Stock Holding History

Palisade Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$268K	Sell	1,412 -165	-10%	-$31K	0.01%	285
2026 Q1	$311K	Buy	+1,577	New	+$304K	0.01%	286

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Palisade Capital Management's AZN Position: Q2 2026 in Review

Palisade Capital Management reduced its AstraZeneca (AZN) stake by 10% in Q2 2026, selling an estimated $31K and leaving 1,412 shares worth $268K. The position accounts for 0.01% of the portfolio, ranked #285.

Palisade Capital Management first reported a position in AZN in Q1 2026 and has held it in 2 quarters since. The position peaked at $311K in Q1 2026. 1,498 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Palisade Capital Management held 1,412 shares of AstraZeneca worth $268K as of Q2 2026.
Palisade Capital Management sold 165 AstraZeneca shares in Q2 2026, an estimated $31K.
AstraZeneca made up 0.01% of Palisade Capital Management's portfolio in Q2 2026, its #285 holding.
Palisade Capital Management first reported a position in AstraZeneca in Q1 2026 and has held it in 2 quarters since.
Palisade Capital Management's AstraZeneca position peaked at $311K in Q1 2026.
1,498 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Palisade Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.